56 results about "Primary osteoporosis" patented technology

Compositions and methods for the treatment of osteoporosis and/or inflammatory joint disease are provided herein. The compositions contain a folate, such as a reduced folate, and folic acid. The folate is preferably 5-methyltetrahydrofolate, and most preferably 5-methyl-(6S)-tetrahydrofolic acid. The folate and folic acid can be given in the same dosage unit or separate dosage units, and more than one dosage unit can be given per dose. The compositions may also contain one or more vitamins and minerals selected from vitamin B12, vitamin B6, vitamin D3, calcium, magnesium, and polyunsaturated fatty acids (PUFAs). These ingredients are optional, but preferable (especially the vitamins and minerals). The compositions may further contain one or more additional ingredients such as vitamins, minerals, and laxatives. The compositions are useful in the treatment of all forms of osteoporosis, including primary osteoporosis and secondary osteoporosis, and/or inflammatory joint diseases, especially in patients having a folic acid metabolism deficiency. The compositions are particularly useful in the treatment of inflammatory joint diseases, with complications that include bone loss, fracture, and osteoporosis. In addition, the compositions are beneficial for the prevention of osteoporosis in subjects who do not yet have the disease, but who are at risk for getting osteoporosis, such as post-menopausal women, subjects with osteopenia (mid thinning of the bone mass), subjects with an inflammatory joint disease, or people who are over the age of 70.

A Chinese medicine for treating the primary osteoporosis is prepared from 8 Chinese-medicinal materials including rehmannia root, yam, Chinese angelica root, tree peony bark, etc through extracting in alcohol or water, peonol extracting, concentrating and shaping.

The invention discloses application of a compound traditional Chinese medicine to prevention and treatment of an osteoporosis disease, belonging to new application of the traditional Chinese medicine. The compound traditional Chinese medicine is prepared from the following Chinese medicinal herbs in percentage by weight: 15-35 percent of glossy privet fruit, 10-25 percent of Japanese thistle herbor root, 5-20 percent of largehead atractylodes rhizome, 5-20 percent of root of red-rooted salvia, 5-15 percent of coptis root, 5-15 percent of pseudo-ginseng root, 5-15 percent of eucommia and 5-15percent of fingered citron. As proved by an experiment, the compound traditional Chinese medicine has remarkable treatment effects on the prevention and treatment of primary osteoporosis, secondary osteoporosis, osteoporosis caused by hyperlipidaemia or an osteoporosis disease caused by glucose metabolism syndrome, definite clinical curative effect and no remarkable side effect according to observation.

The invention relates to a medicament which is a Chinese traditional medicine composition preventing and treating osteoporosis, also to a preparation method thereof, belonging to the technical field of medicament. The medicament is mainly made from 25-40% of rhizoma drynariae, 20-35% of barrenwort, 10-25% of radix achyranthis bidentatae, 10-25% of eucommia and 5-15% of antler sheets. The preparation processes are weighing rhizoma drynariae, barrenwort, radix achyranthis bidentatae, eucommia and antler sheets, sequentially extracting radix achyranthis bidentatae with alcohol and filtering to obtain filtrate I and dregs, decocting dregs, rhizoma drynariae, barrenwort and antler sheets with water, filtering to obtain filtrate II, combining the filtrate I and II, and concentrating to make into liquid medicine containing active components. The Chinese traditional medicine formulation provided by the invention has low side effect and relatively good effect on preventing and treating primary osteoporosis.

The invention belongs to the traditional Chinese medicine field, and relates to a traditional Chinese medicine preparation for treating primary osteoporosis and a preparation method. The compound preparation follows a therapeutic principle of nourishing kidney yin, and employs water extracts of wolfberry, cornus officinalis, Chinese yam, semen cuscutae, deerhorn glue, glue of tortoise plastron, big rehmanniae vaporata, ligustrum lucidum and by mixing with an auxiliary material, the above materials are pelletized and performed with tabletting to prepare the compound preparation. The result of the animal experiments shows that the compound preparation bone resorption and bone formation with high level due to ovariectomy can be reduced, a balance state that the bone formation is greater than the bone resorption can be recovered, and the bone mass is increased; osteocalcin secretion can be promoted, so that the lipoblast differentiation capability can be inhibited. The compound preparation can improve the symptom of primary osteoporosis, reduce recurrence and consolidate curative effect; and can avoid the inconvenience of temporary decoction and easy deterioration for long-term placing before administration of a traditional Chinese medicine decoction for the patients.

The present invention relates to a Chinese medicine composition for curing osteoporosis with excellent therapeutic effect. Said Chinese medicine composition contains 8 Chinese medicinal materials of epimedium, dipsacus root, salvia root, placenta, prepared flowery knotweed, cooked rehmannia root, oyster shell and corydalis tuber.

The present invention discloses a kind of osteoporosis treating compound Chinese preparation and its preparation process. The osteoporosis treating compound Chinese preparation has the alcohol and/or water extracts of 11 kinds of Chinese medicinal materials, including prepared rhizome of rehmannia, Chinese yam, wolfberry fruit, eucommia bark, dodder seed, etc in certain weight proportion, as the active components. The extracts are mixed and added with proper amount of supplementary material to prepare required preparation form. The Chinese preparation has the functions of nourishing liver and kidney, benefiting Qi and promoting blood circulation, is used in treat primary osteoporosis, and has determined curative effect, use safety, stable quality and high effective rate.

The invention discloses a new purpose of N-(2)-L-alanyl-L-glutamine. The new purpose is characterized in that the purpose is an application of the N-(2)-L-alanyl-L-glutamine or the pharmaceuticaly-acceptable salt, ester and solvate to preparation of medicines for resisting osteoporosis. Through in vivo experiment, the inventor finds that the N-(2)-L-alanyl-L-glutamine can reduce the length of thigh bones, increase the diameter of the thigh bones and reduce the indexes of blood calcium concentration and the like. The new purpose of the N-(2)-L-alanyl-L-glutamine has the advantages that medicines can be applied to treatment for resisting osteoporosis, and have treatment protective effects on primary osteoporosis, secondary osteoporosis and idiopathic osteoporosis.

The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, facture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.

The invention relates to the technical field of cod liver oil, in particular to a blending method of cod liver oil preventing the osteoporosis. The blending method comprises the following steps: extracting the cod liver oil from nontoxic ocean cod liver, then determining the content of vitamin D and vitamin A, then blending into a high-concentration cod liver oil raw material, a ratio of VD3 unitsto retinol units in the high-concentration cod liver oil is 2:1; and adding antioxidant (vitamin E and the like) of a given ratio, and then blending with the fish oil or vegetable oil to form cod liver oil drops. The technical scheme of the invention aims at preventing the osteoporosis, and mainly targets at the users such as primary osteoporosis patients and critical people such as the elderly and post-menopause women, and can be used for a long time; and 2, the vitamin A units in the invention are about half of the vitamin D units, after the natural cod liver oil is used by the osteoporosispatients for a long time, and the bone metabolism abnormality caused by the deficiency of the vitamin A can be prevented.

The invention discloses a plasma metabonomics analysis method of patient in primary osteoporosis based on somnipathy. The method comprises the following steps: sample preparation: collecting plasma sample of the primary osteoporosis patient of somnipathy people in sleep cognitive behavioral therapy, treating the plasm sample, and then performing the ultra-high-performance liquid chromatography-mass spectrometric detection analysis; determining the somnipathy according to a Pittsburgh sleep quality index table, wherein the ultra-high performance liquid chromatography-mass spectrometric detection analysis is as follows: performing chromatographic separation on a serum sample, and adopting mass spectrometric detection analysis; performing data analysis extraction and aligning instrument original data to acquire the data which is free from noise interference and can be used for statistical analysis; analyzing the data through the orthogonal partial least square judgement analysis and paired sample T test to acquire the difference metabolite between two groups, and performing initial identification and verification on the substances by combining the existing literature report. The method can provide beneficial technical support for the early prediction and prognosis of the somnipathy people in the primary osteoporosis occurrence.

The invention provides a traditional Chinese medicine for treating primary osteoporosis and a preparation method thereof. The traditional Chinese medicine is prepared from the following medicinal raw materials: cortex acanthopanacis giraldii, tortoise plastron, aralia elata, polygonatum kingianum, morinda officinalis, radix salviae miltiorrhizae, red yeast rice, unpleasant swallowwort herb, anthriscus sylvestris, drumfish, siberian nitraria fruit, meadow fescue, ligamentum cervi, franchet peashrub flower root, membranaceous beautyleaf root, radix dipsaci, tendrilleaf solomonseal rhizome, ursine seal testes and penis, Chinese yam and david deer horn. By utilizing the traditional Chinese medical theory, the traditional Chinese medicine has the advantages of small side effect, good curative effect, low cost, high cure rate, no drug resistance and convenience in taking when used for treating primary osteoporosis.

The invention discloses a biomarker for detecting osteoporosis as well as a preparation method and application of an activatable near-infrared fluorescent probe of the biomarker. The biomarker provided by the invention has negative correlation with various primary osteoporosis. The activatable near-infrared probe of the biomarker comprises a fluorescent strand, a quenching strand and a fuel strand. A specific preparation method comprises the following steps: mixing a Cy5-labeled DNA fluorescent strand (FDA), a BHQ3-labeled DNA quenching strand (QDA) and a hybridized connection DNA strand (Linker DNA) according to a proper ratio, and conducting reacting to obtain the probe. The probe of the invention has the advantages of simple preparation, sensitive detection, good selectivity and the like. The probe can be used as a new index to monitor bone mass change, provides a new candidate means for clinical diagnosis of osteoporosis, and provides a new approach for personalized treatment and prognosis monitoring of osteoporosis.

An oral liquid of donkey-hide gelatin for treating primary osteoprosis and rickets and improving immunity is prepared from donkey-hide gelatin, oyster shell, wolfberry fruit, astragalus root, pilose asiabell root, sorbic acid, water etc.

The invention provides a traditional Chinese medicinal composition pulvis for treating primary osteoporosis. The traditional Chinese medicinal composition comprises the following components: safflower, cistanche deserticola, fructus cnidii, pyrola, drynaria rhizome, suberect spatholobus stem, dendrobe, black sesame, herba lycopi, Chinese yam, tuckahoe and codonopsis pilosula. The traditional Chinese medicinal composition can provide positive interference and treatment on primary osteoporosis, relieve the bone ache of a patient, improve the function of joints, improve the action ability in daily life and reduce the risk of bone fracture, and is low in side effect and low in price at the same time.

Compositions and methods for the prevention and treatment of osteoporosis are provided herein. The compositions contain one or more isoflavones, such as genistein and derivatives thereof, in combination with one or more folates, such as a reduced folate and/or folic acid; and/or one or more polyunsaturated fatty acids (PUFAs), such as an omega-3 and/or omega-6 fatty acid. The isoflavones, folates and/or essential fatty acid may be administered together or in separate dosage units. The compositions may optionally contain other vitamins, minerals, and ingredients, such as, emollient laxatives. The compositions are useful in the treatment of all forms of osteoporosis, including primary osteoporosis and secondary osteoporosis, and/or inflammatory joint diseases, especially in patients having a folic acid metabolism deficiency. The compositions are particularly useful in the treatment of inflammatory joint diseases, with complications that include bone loss, fracture, and osteoporosis. In addition, the compositions are beneficial for the prevention of osteoporosis in subjects who do not yet have the disease, but who are at risk for getting osteoporosis, such as post-menopausal women, subjects with osteopenia (mid thinning of the bone mass), subjects with an inflammatory joint disease, or people who are over the age of 70.

The invention discloses a Chinese herbal medicine compound preparation for treating primary osteoporosis. The preparation is prepared from a kidney tonifying Chinese herbal medicine and medical adjuvant. The kidney tonifying Chinese herbal medicine is prepared from, by weight, 30-9 parts of Herba epimedii, 30-9 parts of Rhizoma Drynariae, 30-9 parts of glossy privet fruit, 30-9 parts of Achyranthes bidentata and 25-6 parts of Angelica pubescens. According to the preparation, the treating rule of kidney warming and reinforcing is followed. Animal experiments show that high-level bone resorption and bone formation caused by ovariectomization can be reduced, so that a balanced state that bone formation is higher than bone resorption is recovered, and the bone mass is increased; osteocalcin secretion is promoted, and the osteogenic differentiation capacity is improved. By means of the preparation, symptoms of primary osteoporosis can be relieved, recurrence is reduced, and the therapeutic effect is consolidated; the problems of temporary decoction before taking Chinese herbal decoction, molding and deterioration due to placement for a long time and inconvenience brought to a patient can be avoided.

The invention provides application of long-chain non-coding RNAGAS5 to preparation of a medicament for treating skeleton system diseases. A GAS5 adenovirus is applied to carry out treatment on osteoporosis, and the pharmacological action of the GAS5 adenovirus is similar with that of teriparatide, and both the GAS5 adenovirus and the teriparatide are medicaments for promoting bone formation. The difference is that the GAS5 is naturally expressed in various types of cells in vivo, has no specific glandular secretion and cannot cause corresponding inhibition from endocrine glands of the human body; and the GAS5 only promotes MSCs to be differentiated into bone cells in vivo, and has no obvious influence on osteoclast. Therefore, the long-chain non-coding RNAGAS5 is higher in osteoporosis resistance, and has no similar problem of small dosage range of the teriparatide. In addition, due to the unique action mode of the adenovirus, the GAS5 can take an acting effect of resisting to osteoporosis only by injecting in vitro for once, and acceptability and comfort of a patient can be greatly promoted.

The invention discloses a diagnosis tool for primary osteoporosis for postmenopausal women. The diagnosis tool achieves a diagnosis purpose by detecting DHRS12 gene and its expression product in blood. The research proves that compared with normal postmenopausal women, the mRNA expression level of the DHRS12 gene in the patient blood with primary osteoporosis for the postmenopausal women is obviously decreased. According to the correlation existed between the DHRS12 gene and the primary osteoporosis for the postmenopausal women, a kit for diagnosing the primary osteoporosis for the postmenopausal women is prepared, and the kit can be widely used for clinic application.